AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AbbVie Inc. on December 13, 2024, reporting events occurring on December 11, 2024. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a successor within the company's finance organization.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the leadership transition in the Controller role:
- Departure: Kevin K. Buckbee, Senior Vice President and Controller, plans to retire effective March 1, 2025.
- Appointment: David R. Purdue has been appointed Senior Vice President and Controller, effective March 1, 2025.
- Background: Mr. Purdue has served as Vice President, Controller, Commercial Operations since 2022 and has been with AbbVie and its former parent, Abbott Laboratories, since 2003.
Guidance, Outlook, and Compensation
The filing details the compensatory arrangements for the newly appointed officer as of the effective date:
- Base Salary: $550,000 annually.
- Bonus Eligibility: Eligible for the Performance Incentive Plan with a target bonus equal to 85% of base salary, contingent on performance targets.
The filing does not contain guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items beyond the personnel change.
Key Facts for Investor Verification
- Confirm the effective date of the Controller transition is March 1, 2025.
- Verify the total potential annual compensation for the new Controller (Base + Target Bonus).
- Review subsequent filings for any changes to the finance leadership structure or impact on financial reporting timelines.